問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

更新時間：2023-09-19

徐稟智Hsu, Ping-Chih
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

108Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

徐稟智

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

List

19Cases

2022-08-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2019-04-01 - 2025-12-31

Phase II

Active
A Phase II, Single Arm Study Assessing Efficacy of Osimertinib With Savolitinib in Patients With EGFRm+ MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study)

  • Condition/Disease

    Locally Advanced or Metastatic Non Small Cell Lung Cancer

  • Test Drug

    TAGRISSO and Savolitinib

Participate Sites
10Sites

Recruiting10Sites

2018-10-01 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    Durvalumab (MEDI4736)

Participate Sites
11Sites

Recruiting10Sites

Terminated1Sites

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2021-02-01 - 2026-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting8Sites

2023-06-01 - 2025-06-23

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2023-05-01 - 2025-08-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-11-15 - 2024-03-15

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2024-01-22 - 2027-05-27

Phase III

Active
A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  • Condition/Disease

    Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  • Test Drug

    injection

Participate Sites
12Sites

Not yet recruiting1Sites

Recruiting11Sites

2023-01-30 - 2026-04-24

Phase III

Active
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

  • Condition/Disease

    Advanced or Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    Ceralasertib (AZD6738)Durvalumab (MEDI4736)

Participate Sites
8Sites

Not yet recruiting8Sites

2020-09-15 - 2025-10-08

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB